pneumonia
viru
mice
pvm
infect
balbc
mice
induc
bronchiol
lead
fatal
pneumonia
dosedepend
manner
close
parallel
develop
sever
diseas
human
respiratori
syncyti
viru
infect
man
thu
recognis
model
studi
pathogenesi
pneumovirus
model
system
use
investig
deliveri
intern
structur
protein
pvm
potenti
vaccin
strategi
protect
pneumoviru
diseas
replicationdefici
recombin
human
adenoviru
serotyp
vector
construct
express
n
gene
pvm
pathogen
strain
intranas
deliveri
vector
gave
protect
lethal
challeng
dose
pvm
three
differ
mous
strain
protect
last
least
week
postimmunis
whilst
pvmspecif
antibodi
respons
anim
weak
inconsist
prime
strong
pvmspecif
cell
respons
lesser
extent
cell
respons
find
suggest
tcell
respons
may
import
serum
igg
observ
protect
induc
virus
classifi
within
genu
pneumoviru
includ
human
hrsv
bovin
brsv
respiratori
syncyti
virus
pneumonia
viru
mice
pvm
hrsv
import
respiratori
pathogen
caus
approxim
million
case
acut
lower
respiratori
tract
diseas
children
annual
requir
hospitalis
infant
recov
natur
hrsv
infect
suffer
fatal
outcom
sinc
longterm
immun
establish
infect
reoccur
throughout
life
elderli
immunocompromis
individu
lead
seriou
complic
earli
clinic
trial
formalininactiv
hrsv
vaccin
led
exacerb
diseas
subsequ
infect
associ
induct
low
affin
hrsvspecif
antibodi
immun
complex
deposit
complement
activ
immun
respons
subsequ
mani
hrsv
vaccin
strategi
investig
howev
clinic
success
candid
emerg
hrsv
vaccin
candid
often
investig
mice
although
high
challeng
dose
requir
give
diseas
even
pathogenesi
match
seen
sever
affect
human
infant
contrast
low
dose
pvm
natur
rodent
host
give
clinic
sign
rang
upper
respiratori
tract
infect
fatal
pneumonia
pathogenesi
close
resembl
sever
hrsv
diseas
human
make
appropri
system
investig
pneumoviru
pathogenesi
immun
respons
hrsv
vaccin
strategi
focus
stimul
strong
system
humor
respons
f
g
glycoprotein
howev
natur
respons
resolv
pneumoviru
infect
primarili
mediat
tcell
recombin
adenovirus
rad
wide
develop
vaccin
candid
includ
deliv
hrsv
glycoprotein
typic
elicit
potent
h
respons
therefor
evalu
intranas
deliveri
human
rad
type
pvm
recombin
mous
model
protect
pneumovirus
select
rout
sinc
superior
intramuscular
im
deliveri
provid
protect
either
lethal
influenza
viru
challeng
hrsv
replic
lung
also
establish
rout
human
vaccin
focus
intern
protein
http
elsevi
ltd
right
reserv
n
sinc
contain
potent
cytotox
tcell
ctl
epitop
hrsv
b
b
restrict
cell
epitop
pvm
furthermor
vaccin
calv
n
protein
vector
prime
brsvspecif
cell
confer
partial
protect
brsv
challeng
mucos
immunis
mice
hrsv
n
protein
nanoparticl
induc
specif
antibodi
cell
respons
reduc
hrsv
pulmonari
replic
show
contain
n
gene
pvm
abl
elicit
longterm
protect
lethal
pvm
infect
mice
correl
stimul
pvmspecif
tcell
popul
line
persist
pvminfect
cell
design
establish
infect
african
green
monkey
kidney
cell
pvm
strain
multipl
infect
pfu
per
cell
follow
initi
appear
cytopath
effect
loss
cell
medium
replac
everi
day
within
week
growth
persist
infect
cell
detect
subsequ
passag
normal
cell
show
pvm
gene
express
immunofluoresc
western
blot
continu
produc
infecti
viru
detect
growth
medium
cell
cell
cell
cultur
glasgow
minim
essenti
media
gmem
plu
foetal
bovin
serum
fb
gmem
plu
fb
dulbecco
modifi
eagl
media
dmem
plu
fb
respect
pvm
strain
stock
prepar
titrat
cell
describ
previous
propag
cell
cultur
dmem
plu
fb
stock
amplifi
titrat
plaqu
assay
cell
delet
gene
replac
transgen
gener
use
adeasi
tm
adenovir
vector
system
stratagen
accord
manufactur
protocol
pshuttlecmv
plasmid
contain
n
gene
pvm
strain
genbank
amplifi
pcr
cdna
use
primer
includ
appropri
restrict
enzym
site
use
gener
cmv
promot
transgen
region
verifi
sequenc
plasmid
contain
escherichia
coli
lacz
gene
use
similarli
gener
recombin
virus
purifi
twice
caesium
chlorid
densiti
gradient
centrifug
dialys
glycerol
phosphatebuff
salin
pb
male
femal
balbc
mice
breed
coloni
univers
warwick
confirm
pvmfree
serolog
use
week
old
anim
similarli
sourc
inhous
old
mice
purchas
charl
river
anim
care
carri
accord
uk
anim
scientif
procedur
act
approv
univers
warwick
ethic
review
board
mice
alloc
experiment
group
equal
sex
ratio
anaesthetis
intraperiton
inject
ketamin
gg
bodyweight
xylazin
gg
bodyweight
inocul
rad
dose
l
pb
pb
alon
control
anim
repeat
immunis
two
week
interv
anim
challeng
lethal
dose
pfu
pvm
strain
l
pb
clinic
sign
assess
previous
describ
bodyweight
measur
daili
anim
sacrif
welfar
reason
end
experi
cervic
disloc
flatbottom
microtitr
plate
coat
overnight
c
gml
either
purifi
cell
lysat
cell
materi
harvest
fragment
agit
glass
bead
sonic
incub
h
block
buffer
low
fat
dri
milk
pb
contain
wv
tween
pbst
serum
bronchoalveolar
lavag
bal
fluid
obtain
use
ml
pb
per
anim
titrat
threefold
dilut
initi
dilut
block
buffer
antibodi
bound
h
roomtemperatur
rt
well
wash
pbst
horseradish
peroxidis
conjug
goat
antimous
sigma
iggspecif
antibodi
santa
cruz
dilut
block
buffer
ad
h
rt
wash
lwell
mgml
azinobi
acid
diammonium
salt
abt
solut
sigma
ad
absorb
measur
nm
use
labsystem
multiskan
rc
plate
reader
antibodi
level
determin
linear
regress
analysi
valu
express
log
endpoint
titr
statist
analysi
perform
use
mann
whitney
u
test
prism
softwar
spleen
lung
ml
pb
pass
cell
strainer
gener
singlecel
suspens
centrifug
g
histopaqu
sigma
pool
uk
mononuclear
cell
interfac
harvest
wash
pb
resuspend
rpmi
medium
life
technolog
contain
fb
uml
penicillin
g
gml
streptomycin
sulfat
cell
restimul
vitro
pvminfect
mockinfect
antigenpres
cell
apc
ratio
ubottom
plate
contain
l
supplement
uml
recombin
human
roch
gml
brefeldin
calbiochem
h
c
apc
spleen
cell
either
pvminfect
pfucel
mockinfect
cell
lysat
min
c
irradi
rad
wash
restimul
cell
surfac
stain
rat
antimous
allophycocyanin
rat
antimous
phycoerythrin
mab
bd
pharmingen
intracellular
stain
use
cytofixcytoperm
solut
permwash
buffer
accord
manufactur
instruct
bd
bioscienc
rat
antimous
bd
bioscienc
cell
analys
facscalibur
flow
cytomet
bd
bioscienc
data
analys
use
cellquest
softwar
express
pvm
n
cell
cultur
confirm
immunofluoresc
western
blot
respect
data
shown
evalu
protect
mice
immunis
day
day
challeng
day
lethal
dose
pvm
monitor
week
clinic
sign
bodyweight
loss
previous
describ
anim
receiv
pfu
develop
sever
clinic
sign
diseas
signific
weight
loss
upon
challeng
similar
pb
mockimmunis
anim
therefor
protect
data
shown
contrast
anim
receiv
higher
dose
surviv
fig
anim
receiv
pfu
either
recombin
show
transient
c
mockimmunis
pb
control
anim
challeng
day
lethal
dose
pvm
weigh
left
panel
assess
clinic
sign
pvm
diseas
right
panel
daili
durat
experi
weight
express
proport
initi
weight
relev
group
mice
weight
day
zero
taken
clinic
sign
express
scale
healthi
moribund
result
mean
five
mice
group
repres
two
separ
experi
singl
pb
control
group
studi
within
experi
data
group
reproduc
panel
ac
eas
comparison
sign
infect
weight
loss
made
complet
recoveri
fig
b
wherea
anim
immunis
develop
sever
diseas
challeng
equival
mockimmunis
anim
fig
thu
pfu
dose
clear
evid
antigenspecif
protect
elicit
surviv
data
subsequ
experi
summaris
tabl
anim
receiv
pfu
remain
healthi
challeng
fig
b
surprisingli
howev
pfu
control
also
protect
fig
although
contrast
receiv
specif
immunogen
anim
develop
sign
ill
thu
pfu
dose
protect
mice
effect
lethal
challeng
signific
compon
protect
antigennonspecif
nonspecif
protect
clearli
distinct
previous
shown
produc
defectiveinterf
di
influenza
viru
pvm
dibas
protect
undetect
day
postadministr
protect
viru
interferondepend
wherea
protect
last
least
two
week
primeboost
protocol
contrast
effect
pvm
pfu
tabl
surviv
data
anim
challeng
pvm
balbc
pfu
afford
protect
influenza
viru
data
shown
investig
singl
dose
efficaci
mice
immunis
challeng
pvm
six
week
later
mice
given
pfu
develop
transient
weight
loss
elev
clinic
score
made
full
recoveri
stabilis
bodyweight
percent
start
weight
fig
whilst
gave
protect
data
indic
even
singl
dose
pfu
elicit
pvmspecif
protect
although
clearli
protect
regimen
similar
twodos
regimen
one
pfu
dose
gave
full
protect
diseas
whilst
equival
singl
dose
also
protect
lethal
outcom
albeit
sign
diseas
fig
antigenspecif
protect
impli
involv
adapt
respons
respons
vari
outbr
popul
epitop
must
present
highli
polymorph
major
histocompat
complex
mhc
antigen
therefor
test
whether
protect
balbc
mice
mhc
haplotyp
could
replic
mous
strain
b
k
mice
immunis
pfu
rad
twodos
regim
fulli
protect
pvm
immunis
anim
case
anim
remain
healthi
follow
challeng
data
shown
partial
protect
anim
two
five
succumb
challeng
period
although
one
occur
without
prior
elev
clinic
score
may
due
challeng
data
shown
thu
protect
lethal
pvm
infect
rad
pvm
recombin
extend
multipl
mhc
haplotyp
antigenspecif
protect
pvm
observ
four
six
week
primari
immunis
determin
durat
protect
balbc
mice
challeng
week
initi
immunis
pfu
rad
twodos
protocol
fig
older
anim
slightli
less
suscept
pvminduc
diseas
reflect
surviv
pb
mockimmunis
anim
howev
control
anim
show
significantli
greater
weight
loss
clinic
score
immunis
anim
follow
pvm
challeng
timepoint
protect
lethal
pvm
challeng
week
postimmunis
fig
b
whilst
anim
show
weight
loss
particularli
follow
prolong
delay
immunis
challeng
transient
less
sever
mice
show
sever
diseas
similar
mockimmunis
anim
fig
thu
immunis
pfu
elicit
longlast
antigenspecif
protect
mice
sever
lethal
pvm
diseas
vaccin
pfu
elicit
detect
antipvm
serum
igg
day
fig
although
mice
show
respons
day
week
second
immunis
still
detect
pvmspecif
antibodi
vaccin
pfu
gener
greater
antipvm
igg
respons
one
anim
respond
day
increas
averag
titr
among
day
respond
anim
fig
although
anim
develop
detect
antibodi
weak
pvmspecif
antibodi
respons
reflect
intrins
problem
elicit
serum
antibodi
respons
vector
rout
administr
sinc
robust
serum
antibodi
respons
induc
pfu
rad
fig
also
due
assay
fail
detect
antibodi
direct
intern
protein
viru
sinc
assay
highli
effect
detect
bind
nspecif
mab
comparison
either
fspecif
mab
polyclon
sera
pvminfect
mice
fig
determin
whether
antipvm
igg
might
develop
increas
longerterm
experi
anim
immunis
pfu
rad
twodos
regim
serum
analys
elisa
fig
protect
lethal
pvm
challeng
long
last
mice
immunis
day
pfu
dose
b
c
mockimmunis
pb
group
six
immunis
anim
plu
two
mockimmunis
anim
challeng
lethal
dose
pvm
time
point
follow
challeng
mice
weigh
left
panel
assess
clinic
sign
pvm
diseas
right
panel
daili
graph
pb
mockimmunis
anim
gener
take
averag
data
mice
challeng
variou
time
point
dot
line
mean
weight
score
loss
one
anim
group
singl
experi
conduct
number
anim
involv
detail
fig
week
although
anim
possess
antipvm
igg
week
fig
time
point
minor
show
respons
one
anim
develop
detect
antipvm
igg
week
number
respond
magnitud
respons
increas
week
fig
minor
show
detect
respons
time
point
antipvm
igg
antibodi
longer
detect
week
expect
elicit
detect
antipvm
igg
time
fig
contrast
anim
mount
detect
respons
confirm
deliveri
immunogen
fig
absenc
consist
antipvm
antibodi
respons
context
consist
protect
lethal
pvm
challeng
suggest
antipvm
igg
respons
primari
mechan
protect
select
studi
cell
respons
sinc
gener
robust
protect
mice
immunis
pfu
two
dose
regimen
lymphocyt
harvest
analysi
day
intracellular
stain
reveal
major
pvmspecif
tcell
induc
spleen
lung
cell
spleen
lung
contrast
pvmspecif
tcell
observ
data
shown
howev
day
immunis
three
dose
pfu
week
apart
major
pvmspecif
tcell
induc
spleen
cell
compar
fig
notabl
pvmspecif
tcell
detect
lung
lymphocyt
mice
data
shown
may
relat
high
background
respons
observ
lung
lymphocyt
anim
pvmspecif
cell
elicit
fig
pvmspecif
splenocyt
anim
demonstr
induc
signific
pvmspecif
tcell
respons
natur
tropism
mucos
surfac
potent
stimul
adapt
immun
make
attract
candid
vector
recombin
pneumoviru
vaccin
develop
evalu
properti
vector
express
pvm
n
protein
found
immunis
pfu
either
construct
elicit
protect
pvm
lethal
diseas
protect
maintain
week
twodos
regimen
least
six
week
singl
immunis
protect
also
extend
mous
strain
three
differ
mhc
haplotyp
weak
inconsist
antipvm
serum
igg
respons
detect
immunis
anim
reliabl
protect
lethal
pvm
challeng
indic
correl
humor
respons
protect
notabl
antipvm
igg
declin
undetect
level
week
post
immunis
yet
anim
still
protect
specif
protect
explain
prime
rapid
pvmspecif
antibodi
respons
differ
specif
igg
titr
control
vector
anim
postchalleng
data
shown
pvmspecif
antibodi
respons
might
weak
pvm
n
protein
contain
strong
bcell
epitop
rout
administr
could
elicit
respons
latter
unlik
sinc
express
hrsv
antigen
elicit
good
serum
igg
respons
deliv
rout
immunis
reliabl
elicit
igg
also
consid
whether
protocol
might
elicit
greater
mucos
serum
antibodi
respons
howev
detect
pvmspecif
iga
bal
fluid
obtain
vaccin
mice
therefor
whilst
remain
possibl
elicit
form
antibodi
assay
could
detect
basi
protect
consid
unlik
contrast
weak
pvmspecif
antibodi
respons
immunis
produc
strong
pvmspecif
cell
respons
spleen
pvmspecif
cell
known
protect
challeng
propos
cellular
respons
major
factor
mediat
specif
protect
studi
sinc
elicit
protect
pvm
challeng
three
differ
mous
strain
suggest
pvm
n
contain
tcell
epitop
recognis
multipl
mhc
background
previou
studi
rad
hrsv
vaccin
candid
includ
vector
express
f
protein
g
protein
element
f
n
protein
elicit
strong
antihrsv
serum
antibodi
potent
tcell
respons
mice
contrast
pvm
studi
vaccin
chimpanze
rad
express
f
n
caus
acceler
onset
weight
loss
mice
follow
hrsv
challeng
differ
like
due
high
titr
hrsv
challeng
inoculum
encount
strong
respons
induc
howev
whilst
studi
demonstr
variou
rad
dose
regimen
inhibit
hrsv
replic
mous
lung
failur
even
highdos
hrsv
challeng
mice
fulli
replic
pathogenesi
rsv
infect
human
mean
implic
studi
protect
human
hrsv
diseas
clear
whilst
pfu
clearli
elicit
antigenspecif
protect
pvm
signific
nonspecif
protect
pvm
diseas
seen
higher
dose
albeit
less
effect
equival
dose
similar
find
nonspecif
protect
report
previous
ferret
immunis
high
dose
rad
though
effect
sar
coronaviru
replic
nose
control
rad
reduc
viru
penetr
lung
consequ
patholog
mani
studi
rad
immunis
includ
empti
rad
nonimmunis
control
nonspecif
protect
would
detect
one
studi
incorpor
control
nonspecif
protect
airway
seen
rad
deliveri
mice
im
differ
find
like
reflect
distinct
immunis
challeng
target
tissu
prevent
nonspecif
local
respons
immunogen
protect
investig
need
understand
natur
scope
nonspecif
protect
respiratori
infect
follow
highdos
intranas
rad
deliveri
one
potenti
issu
extrapol
present
studi
protect
hrsv
human
widespread
immun
might
compromis
immunis
infant
via
matern
antibodi
howev
preexist
circul
antibodi
prevent
respons
mucos
deliv
antigen
suffici
protect
mice
lethal
ebolaviru
challeng
preexist
antibodi
absolut
barrier
effect
use
altern
vector
base
either
human
ad
type
lower
seropreval
nonhuman
ad
chimer
vector
substitut
key
antigen
region
may
use
although
altern
ad
type
may
share
strong
immunogen
summari
shown
replicationdefici
vector
express
intern
antigen
pvm
elicit
robust
protect
pvm
diseas
multipl
mous
strain
deliv
protect
gener
singl
dose
twodos
regim
provid
longterm
protect
pvm
pathogenesi
rodent
similar
hrsv
infect
human
find
success
protect
diseas
model
suggest
similar
strategi
could
appli
protect
hrsv
diseas
human
author
declar
conflict
interest
